BIT:BIO2

Stock Analysis Report

Executive Summary

BioDue S.p.A. develops, manufactures, and markets cosmetics, food supplements, and medical devices.

Snowflake

Fundamentals

Excellent balance sheet with moderate growth potential.

Risks

  • BioDue is covered by less than 3 analysts.

Share Price & News

How has BioDue's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

BIO2

0.1%

IT Personal Products

-0.2%

IT Market


1 Year Return

15.8%

BIO2

14.6%

IT Personal Products

-0.3%

IT Market

BIO2 outperformed the Personal Products industry which returned 14.6% over the past year.

BIO2 outperformed the Market in Italy which returned -0.3% over the past year.


Share holder returns

BIO2IndustryMarket
7 Day0%0.1%-0.2%
30 Day0.6%1.9%5.9%
90 Day21.5%-1.4%2.3%
1 Year18.0%15.8%17.3%14.6%4.0%-0.3%
3 Year51.9%45.7%46.1%36.1%31.4%13.4%
5 Yearn/a104.1%81.8%13.3%-31.1%

Price Volatility Vs. Market

How volatile is BioDue's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioDue undervalued based on future cash flows and its price relative to the stock market?

17%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

BioDue's share price is below the future cash flow value, but not at a moderate discount (< 20%).

BioDue's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

BioDue is good value based on earnings compared to the Europe Personal Products industry average.

BioDue is overvalued based on earnings compared to the Italy market.


Price Based on Expected Growth

BioDue is poor value based on expected growth next year.


Price Based on Value of Assets

BioDue is overvalued based on assets compared to the Europe Personal Products industry average.


Next Steps

Future Growth

How is BioDue expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

17.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioDue's revenue is expected to grow by 8.9% yearly, however this is not considered high growth (20% yearly).

BioDue's earnings are expected to grow by 17.7% yearly, however this is not considered high growth (20% yearly).

BioDue's revenue growth is expected to exceed the Italy market average.

BioDue's earnings growth is expected to exceed the Italy market average.

BioDue's earnings growth is expected to exceed the low risk savings rate of 2.9%.


Earnings per Share Growth Estimates


Future Return on Equity

BioDue is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has BioDue performed over the past 5 years?

23.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioDue has delivered over 20% year on year earnings growth in the past 5 years.

BioDue's 1-year earnings growth is negative, it can't be compared to the 5-year average.

BioDue's 1-year earnings growth is negative, it can't be compared to the Europe Personal Products industry average.


Return on Equity

BioDue has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

BioDue used its assets more efficiently than the Europe Personal Products industry average last year based on Return on Assets.


Return on Capital Employed

BioDue's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is BioDue's financial position?


Financial Position Analysis

BioDue is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioDue's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BioDue's level of debt (46.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (103.1% vs 46.8% today).

Debt is well covered by operating cash flow (39.7%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 64.9x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.1x debt.


Next Steps

Dividend

What is BioDue's current dividend yield, its reliability and sustainability?

2.02%

Expected Dividend Yield


Dividend Yield and Payments Analysis

BioDue's pays a lower dividend yield than the bottom 25% of dividend payers in Italy (1.98%).

BioDue's dividend is below the markets top 25% of dividend payers in Italy (4.35%).

Whilst dividend payments have been stable, BioDue has been paying a dividend for less than 10 years.

Dividend payments have increased, but BioDue only paid a dividend in the past 3 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (3.6x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (3.4x coverage).


Next Steps

Management

What is the CEO of BioDue's salary, the management and board of directors tenure and is there insider trading?


CEO

Vanni Benedetti (51yo)

9.7yrs

Tenure

0

Mr. Vanni Benedetti serves as the Chairman of the Board of Directors at BioDue S.p.A. and has been its Chief Executive Officer since 2010 and its Director since 1993. 


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Vanni Benedetti (51yo)

    Chairman of the Board of Directors & CEO

    • Tenure: 9.7yrs

Board Members

  • Vanni Benedetti (51yo)

    Chairman of the Board of Directors & CEO

    • Tenure: 9.7yrs
  • Roberto Nisica

    Director

    • Tenure: 0yrs
  • Enrico Russo

    Vice Chairman of the Board

    • Tenure: 0yrs
  • Luca Sforazzini

    Director

    • Tenure: 0yrs
  • Conti Luciano

    Chairman of the Board of Statutory Auditors

    • Tenure: 0yrs
  • Bartolini Alfredo

    Statutory Auditor

    • Tenure: 0yrs
  • Bagnoli Luca

    Statutory Auditor

    • Tenure: 0yrs

Company Information

BioDue S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioDue S.p.A.
  • Ticker: BIO2
  • Exchange: BIT
  • Founded: 1986
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: €71.406m
  • Shares outstanding: 11.09m
  • Website: https://www.biodue.com

Location

  • BioDue S.p.A.
  • Via Ambrogio Lorenzetti, 3/a
  • Sambuca
  • Tavarnelle Val di Pesa
  • Florence
  • 50028
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIO2BIT (Borsa Italiana)YesShares CapitalITEURMay 2015

Biography

BioDue S.p.A. develops, manufactures, and markets cosmetics, food supplements, and medical devices. The company produces liquid and solid food supplements, cosmetics, medical devices, and herbal products o ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 21:45
End of Day Share Price2019/09/20 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.